Development of a Large-Scale Stereoselective Process for (1R,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine Hydrochloride
- 20 June 2007
- journal article
- Published by American Chemical Society (ACS) in Organic Process Research & Development
- Vol. 11 (4) , 726-730
- https://doi.org/10.1021/op7000589
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- A Highly Enantioselective, Pd–TangPhos‐Catalyzed Hydrogenation of N‐TosyliminesAngewandte Chemie International Edition in English, 2006
- Development of the commercial process for Zoloft®/sertralineChirality, 2005
- BicifadineDrugs of the Future, 2005
- Approaching Highly Enantioselective Reductive AminationSynlett, 2004
- DOV 216,303, a “Triple” Reuptake Inhibitor: Safety, Tolerability, and Pharmacokinetic ProfileThe Journal of Clinical Pharmacology, 2004
- Highly Efficient Synthesis of β-Amino Acid Derivatives via Asymmetric Hydrogenation of Unprotected EnaminesJournal of the American Chemical Society, 2004
- A New and Simplified Process for Preparing N-[4-(3,4-Dichlorophenyl)-3,4-dihydro-1(2H)-naphthalenylidene]methanamine and a Telescoped Process for the Synthesis of (1S-cis)-4-(3,4-Dichlorophenol)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine Mandelate: Key Intermediates in the Synthesis of Sertraline HydrochlorideOrganic Process Research & Development, 2004
- Highly Diastereoselective Heterogeneously Catalyzed Hydrogenation of Enamines for the Synthesis of Chiral β-Amino Acid DerivativesJournal of the American Chemical Society, 2004
- Industrial Methods for the Production of Optically Active IntermediatesAngewandte Chemie International Edition in English, 2004
- Antidepressant-like actions of DOV 21,947: a “triple” reuptake inhibitorEuropean Journal of Pharmacology, 2003